Perspective Therapeutics Completes Recruitment For First Patient Cohort In Phase 1/2a Dose Escalation Trial Of VMT01 In Malignant Melanoma
Portfolio Pulse from Benzinga Newsdesk
Perspective Therapeutics has completed recruitment for the first patient cohort in its Phase 1/2a dose escalation study of 212Pb-VMT01, a targeted alpha-particle therapy for the treatment of MC1R-positive metastatic melanoma. The trial is a multi-center open-label dose escalation, dose expansion study of 212Pb-VMT01 in subjects with histologically confirmed melanoma and positive MC1R imaging scans. The first part of the study is a dose escalation phase to determine the Maximum Tolerated radioactivity Dose (MTD) or Maximum Feasible radioactivity Dose (MFD) following a single administration of 212Pb-VMT01.
October 16, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Perspective Therapeutics' completion of recruitment for the first patient cohort in its Phase 1/2a dose escalation study of 212Pb-VMT01 could potentially accelerate the development timeline of the therapy. This could have a positive impact on the company's stock in the short term.
The completion of patient recruitment for the first cohort in the Phase 1/2a trial of 212Pb-VMT01 indicates progress in the development of the therapy. This could potentially accelerate the development timeline, which could positively impact investor sentiment and the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100